Decentralized Clinical Trials in 2026: What Site Networks Need to Know

Decentralized Clinical Trials Have Matured Past the Buzzword Phase

Decentralized clinical trials (DCTs) were the most talked-about shift in clinical research operations coming out of the pandemic era, and by 2026 the hype cycle has settled into something more useful: a set of specific, well-understood tools that sponsors mix into traditional site-based studies rather than a wholesale replacement of the site model. For site networks and independent research sites, understanding exactly which decentralized elements are actually being adopted, and what that means operationally, matters more than tracking the DCT trend in the abstract.

The current reality is that very few studies run as fully decentralized, and site-less trials remain the exception rather than the norm, especially outside of a handful of low-complexity indications. What has become common is the hybrid trial, which layers decentralized elements onto a traditional site-based structure. Understanding this hybrid model is the key to positioning a site network correctly.

The Decentralized Elements Sponsors Actually Use

Rather than a single "decentralized" category, sponsors typically select from a menu of specific tools:

• Electronic patient-reported outcomes (ePRO), now close to standard in most therapeutic areas, replacing paper diaries with app-based or web-based data collection
• Remote monitoring visits, where CRAs conduct source data verification through secure video or remote system access rather than traveling to the site for every visit
• Wearable and connected device endpoints, particularly common in cardiology, metabolic disease, and neurology studies where continuous data (heart rate variability, glucose monitoring, activity levels) provides richer endpoints than periodic in-clinic measurement
• Local labs and local imaging, allowing patients to complete routine assessments closer to home rather than traveling to the primary site
• Direct-to-patient drug shipment, used selectively, particularly in later-phase or long-term extension studies where the safety profile is well established
• Telehealth visits for select study visits, typically follow-up or safety check visits rather than screening or primary endpoint visits

What This Means Operationally for a Site

Sites that want to remain competitive for studies incorporating these elements need infrastructure and workflow changes that go beyond simply "being willing" to support decentralized components. Sponsors are now asking feasibility questions that test actual operational readiness:

• Does the site have a reliable telehealth platform already integrated into clinic workflow, or would this be a first-time implementation for the study team?
• Can coordinators support ePRO compliance monitoring, following up with patients who miss electronic diary entries, which requires different workflow discipline than paper-based tracking?
• Does the site have experience receiving and reconciling wearable device data streams, including handling connectivity gaps and device malfunctions?
• Can the site's IT infrastructure support the data security requirements that come with connected devices and remote data transmission?

Sites that can answer these questions with specifics from prior studies, rather than a general willingness to try something new, present a meaningfully stronger feasibility profile for hybrid decentralized protocols.

The Patient Burden Argument, and Why It Matters for Enrollment

The primary driver behind sponsor interest in decentralized elements isn't technological novelty, it's patient burden reduction, which directly affects enrollment and retention. A study with fewer required in-person visits, more flexible visit windows, and options for remote data collection consistently shows better retention numbers, particularly in indications with a geographically dispersed or mobility-limited patient population, such as rare disease, certain oncology populations, and elderly-heavy indications like cardiology and neurology.

For a site network, this creates a genuine business development argument: a site or network that can demonstrably reduce patient burden through hybrid decentralized support isn't just checking a technology box, it's offering the sponsor a credible path to hitting enrollment and retention targets that a fully traditional site might struggle with.

Site Networks Have a Structural Advantage

This is one area where multi-site site networks, particularly those embedded inside a broader health system or urgent care network, have a real structural advantage over single-site independent research clinics. A network spanning multiple geographic locations under a shared operational and regulatory infrastructure can offer sponsors something a single site cannot: the ability to let patients complete certain visits at whichever network location is closest to them, without the sponsor needing to negotiate and activate a formal secondary site.

This "hub and spoke" model, where one site holds the primary IRB and regulatory relationship while multiple locations support local visit completion, is becoming an increasingly common way for embedded research networks to compete for enrollment-heavy, geographically distributed studies that would otherwise require the sponsor to activate many small independent sites.

Where Decentralized Trials Are Not the Right Fit

It's worth being direct about the limits here, because overselling decentralized capability to a sponsor whose protocol doesn't actually support it damages credibility. Decentralized elements remain a poor fit for:

• Early-phase studies requiring intensive in-clinic monitoring, such as first-in-human or dose-escalation studies
• Protocols with complex procedural endpoints that genuinely require in-person clinical assessment, such as certain imaging-based primary endpoints
• Populations with low technology access or literacy, where app-based ePRO compliance would meaningfully harm data quality rather than improve retention
• Indications requiring immediate safety monitoring capability, where remote visits introduce real clinical risk

A site network that can articulate these limits clearly, rather than promising decentralized support for every protocol regardless of fit, builds more sponsor trust than one that oversells its technology capability across the board.

The Regulatory Backdrop

FDA guidance on decentralized trial elements has continued to mature, with clearer expectations around data integrity for remote data collection, informed consent processes for remote enrollment, and sponsor oversight responsibilities when third-party technology vendors are involved in data capture. Sites supporting decentralized elements need study coordinators and regulatory staff who understand these expectations well enough to manage them correctly, since ultimate responsibility for GCP compliance still sits with the site and the principal investigator, regardless of how much of the visit occurs remotely.

Vendor Relationships: The Layer Most Sites Underestimate

Hybrid decentralized trials typically introduce a new set of third-party technology vendors into a study, from ePRO platform providers to wearable device manufacturers to direct-to-patient shipping logistics companies. Sites often assume these vendor relationships are entirely managed by the sponsor or CRO, but in practice, site staff end up troubleshooting device connectivity issues, patient app login problems, and shipment delays directly with patients, even when the formal vendor contract sits with the sponsor.

Sites that build even a basic internal playbook for the most common vendor platforms, covering how to walk a patient through app setup, who to contact when a wearable device stops transmitting data, and what the expected turnaround is for a shipping delay, reduce the operational friction that otherwise falls entirely on coordinators mid-study. This is a relatively low-cost investment that shows up in retention and protocol deviation metrics, which sponsors track and remember for future site selection.

Training Coordinators for a Hybrid Model

Traditional coordinator training focuses heavily on in-person visit conduct, source documentation, and adverse event reporting. Hybrid decentralized studies require an additional layer of training that many sites are still building out:

• Remote consent processes, including how to conduct and document informed consent when part of the process happens through a video visit or electronic signature platform
• ePRO compliance monitoring workflows, since a coordinator now needs to proactively track electronic diary completion rates and follow up with patients who lapse, rather than simply reviewing a paper diary at the next in-person visit
• Remote monitoring visit preparation, ensuring source documents are digitized and accessible for a CRA conducting verification remotely rather than physically in the site's regulatory binder
• Device troubleshooting basics, enough working knowledge of common wearable and connected device issues to triage a patient's problem before escalating to the vendor's technical support line

Sites that invest in this training proactively, rather than learning it study by study under pressure, consistently show better ePRO compliance rates and fewer missed remote visits, both of which sponsors track closely as leading indicators of study quality.

A Readiness Checklist for Hybrid Decentralized Studies

Sites preparing to compete for studies with meaningful decentralized components benefit from working through a specific operational readiness checklist ahead of time, rather than discovering gaps mid-study:

• A validated, HIPAA-compliant telehealth platform already integrated into standard clinic workflow, tested with actual patients before a study requires it
• A documented process for ePRO compliance monitoring, including who is responsible for following up with patients who miss electronic diary entries and how often that follow-up occurs
• IT infrastructure capable of receiving, storing, and reconciling wearable or connected device data streams securely
• A written remote consent procedure that has been reviewed and approved by the site's IRB in advance, rather than developed reactively for a specific study
• Coordinator training completed on device troubleshooting basics and remote monitoring visit preparation
• A clear internal point of contact for escalating technology vendor issues that coordinators cannot resolve directly with patients

Frequently Asked Questions on Decentralized Clinical Trials

Are fully decentralized, site-less trials becoming the norm?

No. Fully decentralized trials remain a small minority of active studies, generally limited to specific low-complexity indications such as certain post-marketing safety studies or straightforward chronic disease registries. The dominant model in 2026 is the hybrid trial, which layers select decentralized elements onto a traditional site-based structure.

What decentralized element are sponsors adopting fastest right now?

Electronic patient-reported outcomes and remote monitoring visits remain the two most widely adopted elements, largely because they require the least change to core visit structure while still meaningfully reducing sponsor and site administrative burden.

Does supporting decentralized elements require significant capital investment for a site?

Not usually. Most decentralized infrastructure, such as telehealth platforms and ePRO systems, is provided or licensed by the sponsor or CRO for the specific study. The investment a site actually needs to make is in coordinator training and workflow redesign, which is a much lower capital cost than technology procurement, but it does require deliberate planning rather than assuming staff will absorb it without preparation.

How should a site talk about decentralized capability in a feasibility questionnaire without overselling it?

Be specific about what has actually been done in prior studies rather than making a general capability claim. A response describing exact ePRO platforms used, remote monitoring visit counts completed, and coordinator training completed carries far more credibility with an experienced feasibility reviewer than a general statement of willingness to support decentralized elements.

Conclusion

The decentralized clinical trial trend has settled into a durable, practical reality: most studies now include some hybrid mix of remote and in-person elements, and the sites winning allocation for these protocols are the ones with genuine operational readiness, not just stated willingness. For site networks, especially those embedded in larger care delivery systems, building real hybrid trial infrastructure, from telehealth platforms to multi-location visit support to coordinator training for remote workflows, has become a legitimate competitive differentiator in sponsor feasibility evaluations, and one that directly supports the enrollment and retention numbers sponsors are increasingly building into their site selection models.